Mitochondria: the gateway for tamoxifen-induced liver injury

Mariana P C Ribeiro1, Armanda E Santos1, José B A Custódio1

  • 1Center for Neuroscience and Cell Biology, University of Coimbra, 3000-354 Coimbra, Portugal; Laboratory of Biochemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.

Toxicology
|June 3, 2014
PubMed

Insights

Tamoxifen (TAM) causes liver injury by damaging mitochondria, while its metabolite endoxifen (EDX) is safer. Monitoring TAM levels and liver function is crucial due to variable metabolism and toxicity risks.

Area of Science:

  • Hepatology
  • Mitochondrial Biology
  • Pharmacology

Background:

  • Tamoxifen (TAM) is a standard breast cancer treatment.
  • TAM frequently causes liver injury, including hepatic steatosis and steatohepatitis.
  • Mitochondrial dysfunction is a key mechanism in TAM-induced hepatotoxicity.

Purpose of the Study:

  • To review the mitochondrial effects of TAM and its metabolites.
  • To elucidate the role of mitochondria in TAM-induced liver injury.
  • To discuss clinical implications for TAM therapy.

Main Methods:

  • Review of existing literature on TAM, its metabolites, and mitochondrial function.
  • Analysis of studies investigating TAM's impact on liver cells and mitochondria.
  • Correlation of metabolic variability with clinical outcomes and liver toxicity.

Main Results:

  • TAM significantly impacts mitochondrial function, contributing to liver damage.
  • Endoxifen (EDX), a TAM metabolite, shows minimal mitochondrial effects and is better tolerated.
  • CYP2D6 genetic polymorphisms and drug interactions cause variable TAM metabolism and unpredictable toxicity.

Conclusions:

  • Mitochondrial dysfunction is central to TAM-induced hepatotoxicity.
  • EDX presents a potentially safer alternative to TAM.
  • Therapeutic drug monitoring and liver function assessment are vital for patients on TAM therapy.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.8K
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
151
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
291